The abstract is read at the publisher; the summary is JClub's.
ctDNA NGS profiling in 10,937 patients with advanced biliary tract cancers detects ESCAT actionable genomic alterations at rates comparable to tissue testing, with faster turnaround.
- Why it matters: Tissue NGS is often constrained by limited access and insufficient tumor material, even as targeted therapies expand and require molecular biomarker testing.
- What they did: In a second retrospective cohort of 126 Spanish patients, paired tissue and ctDNA NGS (Guardant Health) were compared for availability, concordance for ESCAT genomic alterations, and turnaround time.
- The result: ctDNA NGS was available in 90% versus 50% for tissue, showed 83% overall concordance for ESCAT alterations (80% for FGFR2 fusions), and had median turnaround time of 8 versus 27 days.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.